Answers are grounded in this paper and cite their sources.
Background/Objectives: Local control remains difficult for patients with locally advanced or unresectable clear cell renal cell carcinoma (ccRCC) who are unsuitable for surgery or systemic therapy. We developed an injectable, thermoresponsive chitosan/β-glycerophosphate hydrogel co-loaded with elemental molybdenum (Mo⁰) and α-phase manganese dioxide (α-MnO₂) as a locally retained intratumoral depot. Methods : Physicochemical properties, redox activity, and Mo/Mn release in phosphate-buffered saline with or without 0.2 mM H₂O₂ were characterized. Cytotoxicity and ferroptosis-associated responses were evaluated in 786-O and A498 ccRCC cells and HK-2 renal tubular epithelial cells using biochemical, molecular, and pharmacological-rescue assays. Antitumor efficacy, tolerability, and elemental biodistribution were assessed after a single 50 µL intratumoral injection in mice bearing established subcutaneous 786-O tumors. Results : CS+MoMn formed a porous, predominantly elastic, self-recovering gel and produced higher Mo and Mn concentrations in the release medium under oxidative conditions during the 14-day study. CS+MoMn reduced A498 and 786-O viability to approximately 35% and 30% respectively, whereas HK-2 viability remained approximately 92%. Treatment depleted glutathione; increased C11-BODIPY oxidation, malondialdehyde, labile Fe²⁺, and 4-hydroxynonenal; suppressed SLC7A11 and GPX4; and increased TFRC and ACSL4. Ferrostatin-1, liproxstatin-1, and deferoxamine substantially rescued tumor-cell viability, and key responses were reproduced in A498 cells. In vivo, CS+MoMn reduced final tumor volume from approximately 580 to 65 mm³ and tumor weight from 0.75 to 0.06 g relative to the blank hydrogel. No overt short-term histopathological, hematological, or biochemical abnormalities were detected, although limited distal elemental distribution occurred. Conclusions : The Mo⁰/α-MnO₂-loaded hydrogel provides a locally retained, oxidation-responsive platform that preferentially induces ferroptosis-associated ccRCC cell death in vitro and suppresses established tumor growth after a single intratumoral administration.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: